Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03089749 · ClinicalTrials.gov registry record
Characterization of Human Autoantibody Titers After Central Nervous System Insult
A clinical trial, sponsored by University of Utah.
- Terminated
- Registry status
- 63
- Enrollment target
NCT03089749: Clinical Trial study, sponsored by University of Utah.
NCT03089749 is a clinical trial that was terminated before completion, run by University of Utah. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03089749 was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The aim of the study is to quantitate Central Nervous System (CNS) autoantibody development in human blood using ELISA after human brain injury, spinal cord injury, and intra-axial brain surgeries.
Primary Outcome
Quantitate CNS autoantibody development and temporal course in human blood using ELISA after human brain injury, spinal cord injury, and intra-axial brain surgeries.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-05-20 |
Why NCT03089749 stopped before completion
NCT03089749 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03089749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03089749 about?
NCT03089749 is a clinical study titled "Characterization of Human Autoantibody Titers After Central Nervous System Insult". The aim of the study is to quantitate Central Nervous System (CNS) autoantibody development in human blood using ELISA after human brain injury, spinal cord injury, and intra-axial brain surgeries.
What is the current status of trial NCT03089749?
This trial is currently terminated. The enrollment target is 63 participants. The study started on 2015-05. Estimated completion is 2019-05-20.
Who is sponsoring clinical trial NCT03089749?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia